Tesamorelin is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Tesamorelin (Synthetic GHRH analog (44 amino acid polypeptide)) is researched primarily for visceral fat reduction, body image improvement, metabolic restoration in HIV lipodystrophy. The most studied GHRH analog with the longest clinical track record — the only peptide with FDA approval specifically for lipodystrophy-associated visceral fat. It belongs to the GHRH analog, growth hormone secretagogue category of compounds.
What Is Tesamorelin?
Tesamorelin (Synthetic GHRH analog (44 amino acid polypeptide)) is a GHRH analog, growth hormone secretagogue. Synthetic 44 amino acid GHRH analog with enhanced metabolic stability and DPP-4 protease resistance.
The most studied GHRH analog with the longest clinical track record — the only peptide with FDA approval specifically for lipodystrophy-associated visceral fat. It has attracted significant research interest for its potential effects on visceral fat reduction, body image improvement, metabolic restoration in HIV lipodystrophy.
How Does Tesamorelin Produce These Benefits?
Activates GHRH receptors on anterior pituitary somatotrophs via cAMP-PKA cascade. Elevated GH drives hepatic IGF-1 production, reducing visceral adiposity through enhanced lipolysis and reduced truncal fat distribution without altering systemic glucose homeostasis.
This multi-pathway activity is why Tesamorelin shows potential across several different applications rather than being limited to a single use case.
Can Tesamorelin Help With Visceral Fat Reduction?
Research suggests Tesamorelin may support visceral fat reduction through its ghrh analog, growth hormone secretagogue activity. Phase III 12-month trial (404 HIV patients): 18% visceral fat reduction vs placebo. Two Phase III trials confirmed VAT reduction. FDA-approved November 2010. Newest formulation Egrifta WR approved 2025.
Protocols targeting visceral fat reduction typically use 2 mg daily administered once daily for ongoing maintenance; demonstrated benefit to 12+ months.
Can Tesamorelin Help With Body Image Improvement?
Research suggests Tesamorelin may support body image improvement through its ghrh analog, growth hormone secretagogue activity. Phase III 12-month trial (404 HIV patients): 18% visceral fat reduction vs placebo. Two Phase III trials confirmed VAT reduction. FDA-approved November 2010. Newest formulation Egrifta WR approved 2025.
Protocols targeting body image improvement typically use 2 mg daily administered once daily for ongoing maintenance; demonstrated benefit to 12+ months.
Can Tesamorelin Help With Metabolic Restoration In Hiv Lipodystrophy?
Research suggests Tesamorelin may support metabolic restoration in HIV lipodystrophy through its ghrh analog, growth hormone secretagogue activity. Phase III 12-month trial (404 HIV patients): 18% visceral fat reduction vs placebo. Two Phase III trials confirmed VAT reduction. FDA-approved November 2010. Newest formulation Egrifta WR approved 2025.
Protocols targeting metabolic restoration in HIV lipodystrophy typically use 2 mg daily administered once daily for ongoing maintenance; demonstrated benefit to 12+ months.
Can Stacking Enhance Tesamorelin Benefits?
Combines with insulin-sensitizing agents for enhanced metabolic restoration. Off-label stacking with testosterone in HIV patients addresses complementary pathways.
See our Tesamorelin stacking guide for detailed combination protocols.
What Is the Bottom Line on Tesamorelin Benefits?
Tesamorelin is researched for visceral fat reduction, body image improvement, metabolic restoration in HIV lipodystrophy. The evidence base includes: Phase III 12-month trial (404 HIV patients): 18% visceral fat reduction vs placebo. Two Phase III trials confirmed VAT reduction. FDA-approved November 2010. Newest formulation Egrifta WR approved 2025.
Tesamorelin is fda-approved (2010) for hiv-associated lipodystrophy. prescription medication. Source from reputable vendors with third-party testing for reliable results.
Complete Guide
Tesamorelin: The FDA-Approved GHRH Analog
Related Reading
- Tesamorelin Dosage Guide
- Tesamorelin Side Effects
- Tesamorelin Stacking Guide
- Tesamorelin Cycle Guide
- Tesamorelin Research
- CJC-1295 Complete Guide
Calculate Your Tesamorelin Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Tesamorelin.
Open Calculator →Research-Grade Sourcing
If you're going to research Tesamorelin, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Tesamorelin?
Tesamorelin (Synthetic GHRH analog (44 amino acid polypeptide)) is a GHRH analog, growth hormone secretagogue. Synthetic 44 amino acid GHRH analog with enhanced metabolic stability and DPP-4 protease resistance. It is researched for visceral fat reduction, body image improvement, metabolic restoration in HIV lipodystrophy.
What is the recommended Tesamorelin dosage?
Common dosages: 2 mg daily administered once daily via subcutaneous injection. Cycle length: ongoing maintenance; demonstrated benefit to 12+ months. Half-life: 26-38 minutes. Use our peptide calculator for exact reconstitution math.
What are the side effects of Tesamorelin?
Well-tolerated. Injection site reactions most common. Transient flushing, headache, dizziness possible early on. No significant metabolic derangements.
Is Tesamorelin safe?
Tesamorelin has shown a favorable safety profile in research. FDA-approved (2010) for HIV-associated lipodystrophy. Prescription medication. All research should follow appropriate safety protocols.